z-logo
open-access-imgOpen Access
MiR-7 Promotes Epithelial Cell Transformation by Targeting the Tumor Suppressor KLF4
Author(s) -
Karla F. Meza-Sosa,
Erick I. Pérez-García,
Nohemí Camacho-Concha,
Oswaldo López-Gutiérrez,
Gustavo PedrazaAlva,
Leonor Pérez-Martı́nez
Publication year - 2014
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0103987
Subject(s) - oncomir , klf4 , microrna , microbiology and biotechnology , biology , cell growth , transcription factor , regulation of gene expression , cell , cell cycle , malignant transformation , cancer research , gene , genetics , sox2
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that have a pivotal role in the post-transcriptional regulation of gene expression and their misregulation is common in different types of cancer. Although it has been shown that miR-7 plays an oncogenic role in different cellular contexts, the molecular mechanisms by which miR-7 promotes cell transformation are not well understood. Here we show that the transcription factor KLF4 is a direct target of miR-7 and present experimental evidence indicating that the regulation of KLF4 by miR-7 has functional implications in epithelial cell transformation. Stable overexpression of miR-7 into lung and skin epithelial cells enhanced cell proliferation, cell migration and tumor formation. Alteration of these cellular functions by miR-7 resulted from misregulation of KLF4 target genes involved in cell cycle control. miR-7-induced tumors showed decreased p21 and increased Cyclin D levels. Taken together, these findings indicate that miR-7 acts as an oncomiR in epithelial cells in part by directly regulating KLF4 expression. Thus, we conclude that miR-7 acts as an oncomiR in the epithelial cellular context, where through the negative regulation of KLF4-dependent signaling pathways, miR-7 promotes cellular transformation and tumor growth.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here